1. Home
  2. AXSM

AXSM

Axsome Therapeutics Inc.

Logo Axsome Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Founded: 2012 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 3.3B IPO Year: 2015
Target Price: $119.92 AVG Volume (30 days): 732.4K
Analyst Decision: Strong Buy Number of Analysts: 12
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -5.27 EPS Growth: N/A
52 Week Low/High: $55.02 - $98.40 Next Earning Date: 05-06-2024
Revenue: $270,600,000 Revenue Growth: 440.80%
Revenue Growth (this year): 43.13% Revenue Growth (next year): 82.37%

Share on Social Networks: